Literature DB >> 6329088

In vitro activities of amphotericin B in combination with four antifungal agents and rifampin against Aspergillus spp.

C E Hughes, C Harris, J A Moody, L R Peterson, D N Gerding.   

Abstract

Strains of Aspergillus fumigatus, Aspergillus flavus, and Aspergillus niger were tested for in vitro susceptibility with a microtiter plate system in buffered yeast-nitrogen base and in buffered minimal essential medium. Isolates were tested against amphotericin B, flucytosine, rifampin, ketoconazole, ICI 153,066, and Bay n 7133 and against combinations of amphotericin B with each of the other five drugs. Combinations of amphotericin B and rifampin were the most active against all three species of Aspergillus. Flucytosine combined with amphotericin B produced little or no reduction of the MICs at which 90% of the strains were inhibited compared with amphotericin B alone. With one exception, the addition of ketoconazole, ICI 153,066, or Bay n 7133 to amphotericin B did not consistently alter the MICs. The addition of ICI 153,066 markedly increased the MICs of amphotericin B against the A. flavus isolates in both media. When the azoles were tested alone, Bay n 7133 was the most active against A. fumigatus, but was two- to fivefold less active against A. flavus. Ketoconazole was the most active azole against A. flavus.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6329088      PMCID: PMC185585          DOI: 10.1128/AAC.25.5.560

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  In vitro studies with combinations of 5-fluorocytosine and amphotericin B.

Authors:  S Shadomy; G Wagner; E Espinel-Ingroff; B A Davis
Journal:  Antimicrob Agents Chemother       Date:  1975-08       Impact factor: 5.191

2.  Cure of Aspergillus ustus endocarditis on a prosthetic valve.

Authors:  J Carrizosa; M E Levison; T Lawrence; D Kaye
Journal:  Arch Intern Med       Date:  1974-03

3.  Susceptibility of Aspergillus to 5-fluorocytosine and amphotericin B alone and in combination.

Authors:  B A Lauer; L B Reller; G P Schröter
Journal:  J Antimicrob Chemother       Date:  1978-07       Impact factor: 5.790

4.  Sino-orbital aspergillosis treated with combination antifungal therapy. Successful therapy after failure with amphotericin B and surgery.

Authors:  V L Yu; G E Wagner; S Shadomy
Journal:  JAMA       Date:  1980 Aug 22-29       Impact factor: 56.272

5.  Therapy of murine aspergillosis with amphotericin B in combination with rifampin of 5-fluorocytosine.

Authors:  J Arroyo; G Medoff; G S Kobayashi
Journal:  Antimicrob Agents Chemother       Date:  1977-01       Impact factor: 5.191

6.  Activity of amphotericin B, 5-fluorocytosine, and rifampin against six clinical isolates of Aspergillus.

Authors:  M Kitahara; V K Seth; G Medoff; G S Kobayashi
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

7.  Combined amphotericin B-flucytosine therapy in Aspergillus pneumonia.

Authors:  S D Codish; J S Tobias; M Hannigan
Journal:  JAMA       Date:  1979-06-01       Impact factor: 56.272

8.  Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro.

Authors:  F C Odds
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

9.  Combination amphotericin B-rifampin therapy for pulmonary aspergillosis in a leukemic patient.

Authors:  B Ribner; G T Keusch; B A Hanna; M Perloff
Journal:  Chest       Date:  1976-11       Impact factor: 9.410

10.  Disposition of ketoconazole, an oral antifungal, in humans.

Authors:  C Brass; J N Galgiani; T F Blaschke; R Defelice; R A O'Reilly; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

View more
  19 in total

Review 1.  Antifungal activity of nonantifungal drugs.

Authors:  J Afeltra; P E Verweij
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-06-26       Impact factor: 3.267

2.  In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents.

Authors:  Eric Dannaoui; Javier Afeltra; Jacques F G M Meis; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

Review 3.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

Review 4.  Aspergillus infections in transplant recipients.

Authors:  Nina Singh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

Review 5.  Compounds active against cell walls of medically important fungi.

Authors:  R F Hector
Journal:  Clin Microbiol Rev       Date:  1993-01       Impact factor: 26.132

6.  Initial use of a broth microdilution method suitable for in vitro testing of fungal isolates in a clinical microbiology laboratory.

Authors:  D M Hacek; G A Noskin; K Trakas; L R Peterson
Journal:  J Clin Microbiol       Date:  1995-07       Impact factor: 5.948

7.  In vitro synergistic interaction between amphotericin B and pentamidine against Scedosporium prolificans.

Authors:  Javier Afeltra; Eric Dannaoui; Jacques F G M Meis; Juan L Rodriguez-Tudela; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

8.  Nikkomycin Z supersensitivity of an echinocandin-resistant mutant of Saccharomyces cerevisiae.

Authors:  M el-Sherbeini; J A Clemas
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

9.  New in vitro assay based on glucose consumption for determining intraconazole and amphotericin B activities against Aspergillus fumigatus.

Authors:  J C Garrigues; G Cadet de Fontenay; M D Linas; M Lagente; J P Seguela
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

10.  Effects of antifungal agent combinations administered simultaneously and sequentially against Aspergillus fumigatus.

Authors:  S Maesaki; S Kohno; M Kaku; H Koga; K Hara
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.